An interventional study of Broccoli sprout extract (BSE) and Placebo Control in Cognitive Dysfunction and Cognitive Decline, sponsored by Pusan National University Yangsan Hospital. Recruiting at 1 site in South Korea. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-01-13.
Sponsored by Pusan National University Yangsan Hospital · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 74 studies in Cognitive Dysfunction with a site in Korea, Republic of — 17 open to participants now, 24 under way, 5 of them phase 3. Cognitive Dysfunction · Korea, Republic of.
Among the 74 studies in Cognitive Dysfunction with a site in Korea, Republic of, this one is the 25th largest by planned enrollment of the 57 interventional ones that give a count, is one of 13 that started in 2025, is one of 37 with no phase, reaches primary completion later than 8 of the 23 other live ones, and was the 71st registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →17 of the 74 studies in Cognitive Dysfunction with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Korea, Republic of, United States, Japan and 1 more country
Ages 55–85
Deepsonbio · Sites in Korea, Republic of
Ages 55–90
NeuroBiogen Co., Ltd · Sites in Korea, Republic of
Ages 50–85
Bristol-Myers Squibb · Sites in Korea, Republic of, United States, Argentina and 16 more countries
Ages 60–85
Hoffmann-La Roche · Sites in Korea, Republic of, United States, Argentina and 12 more countries
Ages 50–90
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 50 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
74 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 13 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 64 across 2,804 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 94 across the 57 interventional studies, 163 across the 17 observational. Of the 34 that completed or were terminated, 2 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 74 have an industry lead sponsor. The 10 most frequent:
Pusan National University Yangsan Hospital is the lead sponsor of 108 studies on the registry; 27 are open to participants now.
Pusan National University Yangsan Hospital has 6 studies filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
10 of the studies in Cognitive Dysfunction with a site in Korea, Republic of that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT07239310DeepsonbioNeuclare Device for Temporary Improvement of Executive Function in Patients With Mild Cognitive Impairment and Prodromal Alzheimer's Disease | 2026-12 |
| NCT07334366Pusan National University Yangsan HospitalBroccoli Sprout Extract for Cognitive Function | 2026-12-30 |
| NCT07011680Pusan National University Yangsan HospitalPhospholipid-rich Dairy Extract for Cognitive Function | 2026-12-30 |
| NCT06786676Amyloid Solution IncA Phase 1 Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of AS-S603 in Healthy Participants | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 74 studies in Cognitive Dysfunction with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial aims to determine whether broccoli sprout extract improves cognitive function in adults with mild cognitive impairment and to assess its safety.
The main questions are:
Researchers will compare broccoli sprout extract to a placebo to evaluate their effectiveness in improving cognitive function in participants.
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
GDS 2: Subjective memory impairment without objective evidence GDS 3: Mild objective memory impairment
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group takes broccoli sporout extract for 12 weeks.
Dietary Supplement: Broccoli sprout extract (BSE)
This group takes placebo for 12 weeks.
Dietary Supplement: Placebo Control
BSE 1,000 mg/day for 12 weeks
Placebo (crystalline cellulosel) 1,000 mg/day for 12 weeks
Change from baseline to 12 weeks in total Computerized NeuroCognitive Function Test score comprising verbal learning test, digit span test, and auditory continuous performance test
The change in total CNT score from baseline to 12 weeks, calculated as the sum of verbal learning test, digit span test, and auditory continuous performance test scores. Higher total CNT scores indicate better neurocognitive function across the domains of memory, attention, and sustained concentration. This composite measure assesses overall cognitive performance, where positive changes (increase in total score) indicate cognitive improvement and negative changes (decrease in total score) suggest cognitive decline.
Time frame: 12 weeks
Change from baseline to 12 weeks in verbal learning test score
The change in verbal learning test score from baseline to 12 weeks, measuring memory and learning capacity. Higher scores indicate better verbal memory and learning ability. This assessment evaluates the ability to acquire, retain, and recall verbal information over multiple learning trials. Positive changes (increase in score) indicate improvement\*\* in verbal memory function, while negative changes (decrease in score) suggest a decline in verbal learning capacity.
Time frame: 12 weeks
Change from baseline to 12 weeks in digit span test score
The change in digit span test score from baseline to 12 weeks, measuring working memory and attention span. Higher scores indicate better working memory and attention capacity. This assessment evaluates the ability to temporarily hold and manipulate numerical information in memory through forward and backward digit recall tasks. Positive changes (increase in score) indicate improvement in working memory capacity, while negative changes (decrease in score) suggest decline in attention and short-term memory function.
Time frame: 12 weeks
Change from baseline to 12 weeks in auditory continuous performance test score
The change in auditory continuous performance test score from baseline to 12 weeks, measuring sustained attention and concentration abilities. Higher scores indicate better sustained attention and concentration capacity. This assessment evaluates the capacity to maintain focused attention and respond appropriately to auditory stimuli over an extended period. Positive changes (increase in score) indicate improvement in sustained attention function, while negative changes (decrease in score) suggest decline in concentration and vigilance capabilities.
Time frame: 12 weeks
Change from baseline to 12 weeks in Korean Mini-Mental State Examination (MMSE-K) total score
The change in MMSE-K total score from baseline to 12 weeks, providing a brief assessment of global cognitive function. Higher scores indicate better global cognitive function. This standardized instrument evaluates orientation, attention, memory, language, and visuospatial abilities. Positive changes (increase in score) indicate improvement in overall cognitive status, while negative changes (decrease in score) suggest decline in cognitive function.
Time frame: 12 weeks
Change from baseline to 12 weeks in serum brain-derived neurotrophic factor (BDNF) concentration
The change in serum BDNF concentration from baseline to 12 weeks, measured in ng/mL or pg/mL. BDNF is a neurotrophin that plays a crucial role in neuronal survival, growth, and synaptic plasticity. Positive changes indicate increased BDNF levels associated with enhanced neuroplasticity and neuroprotection, while negative changes suggest decreased neurotrophic support.
Time frame: 12 weeks
Change from baseline to 12 weeks in serum malondialdehyde (MDA) concentration
The change in serum MDA concentration from baseline to 12 weeks, measured in μmol/L or nmol/mL. MDA is a biomarker of lipid peroxidation and oxidative stress, reflecting cellular damage from reactive oxygen species. Positive changes indicate increased oxidative stress and cellular damage, while negative changes stress and improved antioxidant status.
Time frame: 12 weeks
Change from baseline to 12 weeks in serum superoxide dismutase (SOD) activity
The change in serum SOD activity from baseline to 12 weeks, measured in U/mL or U/mg protein. SOD is a key antioxidant enzyme that catalyzes the dismutation of superoxide radicals, providing cellular protection against oxidative damage. Positive changes indicate enhanced antioxidant capacity and cellular protection, while negative changes suggest reduced antioxidant defense mechanisms.
Time frame: 12 weeks
Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.
Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 20 months is below that.
Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Broccoli sprouts
Pusan National University Yangsan Hospital →